Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-25T23:30:15.923Z Has data issue: false hasContentIssue false
  • English
  • Français

Response to “Germ Line Therapy to Cure Mitochondrial Disease: Protocol and Ethics of In Vitro Ovum Nuclear Transplantation” by Donald S. Rubenstein, David C. Thomasma, Eric A. Schon, and Michael J. Zinaman (CQ Vol. 4, No. 3)

Published online by Cambridge University Press:  01 January 1999

Helen Watt
Helen Watt
Affiliation:
Linacre Centre for Health Care Ethics in London, England
Get access Rights & Permissions [Opens in a new window]

Abstract

Germ-line therapy has long been regarded with great caution both by scientists and by ethicists. Even those who do not reject germ-line therapy in principle have tended to reject it in practice as carrying unacceptable risks in our current state of knowledge. For this reason, a recent paper by Rubenstein, Thomasma, Shon, and Zinaman is unusual in putting forward a serious proposal for the use of germ-line therapy in the foreseeable future.

Type
RESPONSES AND DIALOGUE
Information
Cambridge Quarterly of Healthcare Ethics , Volume 8 , Issue 1 , January 1999 , pp. 88 - 96
Copyright
© 1999 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)